Rakesh Jhunjhunwala’s firm-backed Concord Biotech IPO opens on August 4: Key things to watch out
On August 3, a day before the issue begins to be distributed, there will be a one-day debut of the anchor book.
Money Poise
Concord Biotech, a biotechnology company, plans to release its initial public offering (IPO) for subscription on August 4, making it the second public issue starting the next week after SBFC Finance.
Helix Investment Holdings Pte Limited, the private fund managed by Quadria Capital, has made a sole offer for sale (OFS) of 2,09,000,000 equity shares in the public offering.
The public offering for the Ahmedabad-based pharmaceutical company Rare Enterprises, which was backed by private equity firm Quadria Capital and the estate of the late veteran investor Rakesh Jhunjhunwala, will end on 8 August.
On August 3, a day before the issue's official release, the anchor book will be released for one day.
The news that Concord Biotech plans to go public with an IPO of Rs 1,500-1,600 crore in early August and is hoping for a valuation of $950 million to $1 billion was originally reported by Moneypoise.
Also Read : Over 5 cr ITRs filed for 2022-23 fiscal so far
.jpeg?updatedAt=1701532366224){kind=small}
.jpeg?updatedAt=1701266483633)
.jpeg?updatedAt=1698674282372)
